Project Studie MK3475-716

Basic data

Title:
Studie MK3475-716
Duration:
02/05/2019 to 29/10/2029
Abstract / short description:
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk
Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Haar, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.